Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novozymes Biopharma Announces Collaboration with Almac

Published: Tuesday, October 22, 2013
Last Updated: Tuesday, October 22, 2013
Bookmark and Share
Combined service offers drug development companies efficiencies in time and resource.

Novozymes Biopharma has announced its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

The collaboration will allow clients to utilize Almac’s world-class manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin® Flex technology successfully to their peptide and small molecule drugs.

This subsequently improves the pharmacokinetics and has already been shown to improve drug targeting in oncology and rheumatoid arthritis. Collaborations with commercial partners have already begun and will continue to expand in early 2014.

Novozymes and Almac have a solid history of cooperation in peptide and small molecule conjugation projects. The formalization of this collaboration offers drug developers the immediate benefit of continuity of service provision through the stages of clinical development -delivering efficiencies in time and internal resource, whilst increasing the chances of clinical success.

Clients will also benefit from extensive experience in product and service provision to the pharmaceutical industry with access to a comprehensive level of both technical and regulatory support.

Novozymes’ Recombumin® Flex technology will be the focal point of this collaboration. Novozymes has modified the amino acid sequence of human albumin to increase its receptor affinity, providing novel properties including improved half-life extension and drug targeting.

This technology naturally complements Almac’s expertise in peptide and small molecule manufacturing, and can also be allied to its world-class protein conjugation technology offerings. As a result, clients will be able to successfully use Almac’s technology to link Recombumin® Flex to their drug products as part of one contract service offering.

“By working alongside Almac, we are confident that we will be able to create more opportunities for developers seeking to benefit from the Recombumin® Flex technology,” stated Dermot Pearson, Marketing Director at Novozymes Biopharma. “the advantage of working with two companies well versed in providing products and services to the pharmaceutical industry is that customers gain the assurance that their needs will be provided for, not just in the short term, but right through to commercial supply.”

Denis Geffroy, VP Business Development for Almac stated: “This alliance has clear benefits for companies involved in both drug development and delivery technologies: a complete service can be recommended utilizing the core expertise of both parties at an early stage of clinical development, thus significantly enhancing the success of drug development programmes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Addresses Industry Demand For Multiparticulate Drug Products
In response to increasing client demand for multiparticulate drug delivery systems, Almac Group is providing fluid-bed processing and encapsulation services to its global partners from its UK development and commercial manufacturing facilities.
Monday, October 12, 2015
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
Tuesday, January 08, 2013
Almac Doubles Analytical Capacity in US Headquarters
New Lab investment includes polymorph and salt screening and solid form development.
Friday, February 10, 2012
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!